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the risk of preterm birth: a population-based cohort study
Jue Liu*, Shikun Zhang*, Min Liu, Qiaomei Wang, Haiping Shen, Yiping Zhang
Summary
Background Preterm birth is the leading cause of child death in children younger than 5 years. Large cohort studies in 
developed countries have shown that maternal hepatitis B virus infection is associated with preterm birth, but there 
is little reliable evidence from China and other developing countries, where hepatitis B virus prevalence is intermediate 
or high. Hence, we designed this study to investigate the association between pre-pregnancy hepatitis B virus infection 
and risk of preterm and early preterm birth.
Methods Between Jan 1, 2010, and Dec 31, 2012, we did a population-based cohort study using data from 489 965 rural 
women aged 21–49 years who had singleton livebirths from 220 counties of China who participated in the National 
Free Preconception Health Examination Project. Participants were divided into three groups according to their pre-
pregnancy status of hepatitis B virus infection: women uninfected with hepatitis B virus (control group), women who 
were HBsAg positive and HBeAg negative (exposure group 1), and women who were both HBsAg and HBeAg positive 
(exposure group 2). The primary outcome was preterm birth (gestation at less than 37 weeks). We used log-binomial 
regression to estimate adjusted risk ratios (aRR) of preterm birth for women with pre-pregnancy hepatitis B virus 
infection, and risk of early preterm birth (gestation less than 34 weeks).
Findings 489 965 women met inclusion criteria and were included in this study; of these, 20 827 (4·3%) were infected 
with hepatitis B virus. Compared with women who were not infected with hepatitis B virus, women who were HBsAg 
positive and HBeAg negative had a 26% higher risk of preterm birth (aRR 1·26, 95% CI 1·18–1·34) and women who 
were both HBsAg and HBeAg positive had a 20% higher risk of preterm birth (aRR 1·20, 1·08–1·32). Compared with 
women who were not infected with hepatitis B virus, women who were HBsAg positive and HBeAg negative 
manifested an 18% higher risk of early preterm birth (gestation less than 34 weeks; aRR 1·18, 1·04–1·34) and women 
who were both HBsAg and HBeAg positive had a 34% higher risk of early preterm birth (aRR 1·34, 1·10–1·61). 
Maternal pre-pregnancy hepatitis B virus infection was independently associated with higher risk of preterm birth 
and early preterm birth. These associations were similar in subgroups of participants as defined by baseline 
characteristics.
Interpretation Besides mother-to-child transmission, the risk of preterm birth in women infected with hepatitis B 
virus should not be neglected. Comprehensive programmes that focus on early detection of hepatitis B virus infection 
before pregnancy and provide appropriate medical intervention for women infected with hepatitis B virus before and 
during pregnancy would be helpful in improving maternal and neonatal outcomes and reducing child mortality.
Funding Chinese Association of Maternal and Child Health Studies.
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license.
Introduction
Preterm birth, a birth occurring before 37 completed 
weeks of gestation, is the leading cause of death in 
children younger than 5 years.1 An estimated 14·9 million 
babies, 11·1% of all livebirths worldwide, were born 
preterm in 2010.2 Preterm birth complications are 
estimated to be responsible for roughly 35% of the 
world’s 2·76 million annual neonatal deaths,1 and 
surviving preterm babies are at increased risk of 
neurodevelopmental impairments and respiratory and 
gastrointestinal complications.3 In low-income and 
middle-income countries, babies born before 34 weeks 
of gestation (early preterm birth) have only a 50% chance 
of survival4,5 and the risk of maternal complications after 
early preterm birth is substantial.6 Identifying risk 
factors is crucial for effective prevention, especially for 
early pre term birth. Several maternal factors have been 
associated with preterm birth, such as demographic 
characteristics, nutritional status, pregnancy history and 
current characteristics, infection, adverse behaviours, 
uterine contractions, and cervical length.3 Among these 
factors, viral infection is an important cause of preterm 
birth. Previous studies have reported that maternal 
hepatitis B virus infection was associated with an 
increasing risk of preterm birth,7–14 but some studies 
showed inconsistent results.15–18 The association between 
hepatitis B virus infection and preterm birth is still 
controversial.
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Hepatitis B virus infection is a major health problem, 
causing high mortality and societal burden worldwide.19 
China has the world’s largest burden of hepatitis B virus 
infection, with an estimated 74·6 million people 
chronically infected.20,21 The prevalence of hepatitis B virus 
infection in women of reproductive age and pregnant 
women in China has been estimated at 3·87–9·98%.18,22–27 
Additionally, China has the second largest number of 
preterm births worldwide, with 1·17 million each year. 
However, large cohort studies depicting the association 
between maternal hepatitis B virus infection and preterm 
birth have almost always been done in developed countries 
with a low prevalence of hepatitis B virus infection; little 
reliable evidence exists from China or other developing 
countries where the prevalence of hepatitis B virus 
infection is intermediate or high. Furthermore, little has 
been done to investigate the association between 
pre-pregnancy hepatitis B virus infection and preterm 
birth. From a preventive point of view, identifying this 
association is important because it is relatively easy to 
intervene before pregnancy, and it might provide more 
effective results with respect to the gestational outcome 
for women with hepatitis B virus infection.
We did a large population-based cohort study in China 
to examine the association between maternal pre-
pregnancy hepatitis B virus infection and risk of preterm 
and early pre-term birth.
Methods 
Study design and participants
We did a large population-based retrospective cohort 
study in women of reproductive age (21–49 years) who 
participated in the National Free Preconception Health 
Examination Project (NFPHEP) from Jan 1, 2010, to 
Dec 31, 2012, successfully became pregnant, and then had 
a singleton livebirth in 220 counties in 31 provinces. 
NFPHEP was launched by the Chinese National Health 
and Family Planning Commission and the Ministry of 
Finance in 2010, with the aim to provide free health 
examinations before conception, counselling services for 
reproductive couples who planned to become pregnant 
within the next 6 months, and follow-up of pregnancy 
outcomes in the rural areas. Project-related design, 
organisation, and implementation have been described 
previously.28–30 This study was approved by the Institutional 
Review Board of the Chinese Association of Maternal and 
Child Health Studies. All participants provided written 
informed consent before enrolment.
Procedures
Staff from local communities gathered data on the 
willingness of reproductive couples regarding pregnancy 
and enrolled those couples who had already made plans to 
become pregnant. Trained local health workers 
used a standardised questionnaire to collect baseline 
information from women who participated in the 
NFPHEP, including demographic characteristics (age, 
education level, occupation, ethnicity, and address of 
residence); history of chronic disease (hypertension, 
diabetes, chronic nephritis, thyroid disease, heart disease, 
anaemia, and cancer); history of pregnancy (gravidity and 
parity); and history of adverse pregnancy outcomes 
(spontaneous abortion, induced abortion, stillbirth, and 
preterm birth). Data were inputted into a web-based 
Research in context
Evidence before the study
We searched the published literature for studies on the 
association between hepatitis B virus infection and preterm 
birth through PubMed using the terms “hepatitis B virus” and 
“preterm birth”, including all the reports published in both 
English and Chinese before Sept 20, 2016. We identified 
two large cohort studies on the association between hepatitis B 
virus infection and preterm birth, but these studies were done 
in developed countries where the prevalence of hepatitis B virus 
infection was relatively low. We also identified several studies 
done in developing countries where the prevalence of 
hepatitis B virus infection was relatively high or intermediate. 
However, the results of these studies were controversial.
Added value of this study
In this large population-based cohort study, we examined the 
association between pre-pregnancy hepatitis B virus infection 
and risk of preterm birth in 489 965 women. To our knowledge, 
our study is the first explorative study of maternal 
pre-pregnancy hepatitis B virus infection and preterm birth in a 
large-scale cohort in China. Results from this study showed that 
maternal pre-pregnancy hepatitis B virus infection was 
independently associated with increased risk of preterm birth 
and with early preterm birth (gestation less than 34 weeks). 
Compared with women uninfected with hepatitis B virus, 
women who were infected with hepatitis B virus had a 
20–26% higher risk of preterm birth. Our findings add to the 
improved understanding of prevention and treatment of 
preterm birth, which is a risk factor for mortality in children 
younger than 5 years.
Implications of all the available evidence
This study highlights that, besides mother-to-child transmission, 
the risk of preterm birth in women infected with hepatitis B virus 
should not be neglected. Comprehensive programmes that focus 
on the early detection of hepatitis B virus infection before 
pregnancy, monitor the risk of preterm birth, and provide 
appropriate medical intervention for women infected with 
hepatitis B virus during pregnancy would be helpful in improving 
maternal and neonatal outcomes and reducing child mortality. 
Future research should explore the underlying mechanisms of 
hepatitis B virus infection’s effect on preterm birth and effective 
strategies to reduce the risk of preterm birth among infected 
mothers, especially in developing countries.
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electronic data collection system and sent to the national 
office. Trained qualified local health workers then did pre-
pregnancy physical examinations. They measured 
bodyweight and height using calibrated instruments. 
Body-mass index (BMI) was calculated by dividing the 
weight in kg by the square of the height in m. Blood 
samples were taken and immediately sent to accredited 
local laboratories affiliated with authorised medical 
institutions.
Serum samples were separated and stored at −30°C 
before analysis. All samples were tested for the presence 
of hepatitis B surface antigen (HBsAg) and hepatitis B 
e antigen (HBeAg) using ELISA kits. Local laboratories 
made their own choices regarding reagent kits, all of 
which were approved by the China Food and Drug 
Administration. All reagent kits selected by local 
laboratories were tested by the National Center of Clinical 
Laboratories for Quality Inspection and Detection, with 
reagents produced by Abbott (Abbott Park, IL, USA) as 
the reference standard. Sensitivity, specificity, and κ value 
of the selected reagents from all of the counties 
involved were all higher than 95%. Serum alanine 
aminotransferase quantification (the most commonly 
used enzyme in the assessment of liver function), 
was also done using the kinetic method within 2 h of 
sample arrival at local laboratories. Elevated alanine 
aminotransferase was defined as greater than 40 IU/L. 
The National Center of Clinical Laboratories for Quality 
Inspection and Detection was responsible for the external 
quality assessment biannually, and for quality control.31
HBsAg positivity indicated that a participant was 
infected with hepatitis B virus. If a participant was tested 
as being both HBsAg and HBeAg positive, this indicated 
that virus was actively replicating and the level of 
infectiousness was high. We then divided participants into 
three groups according to their pre-pregnancy status 
regarding HBsAg/HBeAg: women who were HBsAg 
negative, indicating no infection with hepatitis B virus 
(control group); women who were HBsAg positive and 
HBeAg negative (exposure group 1); and women who 
were both HBsAg and HBeAg positive (exposure group 2).
After pre-pregnancy physical examination, all parti-
cipants were followed up by trained local health workers 
by telephone each month. Health workers interviewed 
women face-to-face or by telephone within 3 months after 
conception, recording their last menstrual period, 
cigarette consumption by the women themselves and 
their husbands (they were all married) during pregnancy, 
and alcohol consumption by the women during 
pregnancy. Women were also interviewed face-to-face or 
by telephone 1 month after delivery to collect information 
on hospitals where delivery took place. Local health 
workers then collected detailed information from the 
medical records at these local hospitals with respect to 
pregnancy outcomes, including current pregnancy 
outcome (normal birth, preterm birth, miscarriage, 
induced abortion, or stillbirth), delivery date, gestational 
weeks, and newborn information (singleton or multiple 
births). The study was terminated when women had 
preterm birth or other pregnancy outcomes (such as 
normal birth, spontaneous abortion, induced abortion or 
stillbirth), or when the study reached the end of the 
observation period (Dec 31, 2012).
Outcomes
The primary outcome was preterm birth. We defined 
preterm births as births delivered at gestational ages less 
than 37 weeks and early preterm births as births delivered 
at gestational ages less than 34 weeks. The proportion of 
preterm and early preterm births was measured in 
respect to all singleton livebirths. 
Statistical analysis
We included all women who fitted all inclusion criteria. 
We calculated medians and IQRs for age. We used 
proportions to describe baseline characteristics of the 
participants, such as region and educational levels, and 
the χ² test to compare the distributions of pre-pregnancy 
status of hepatitis B virus infection according to different 
baseline characteristics.
According to the pre-pregnancy status of hepatitis B 
virus infection, participants were divided into three groups: 
women who were HBsAg negative, indicating no infection 
with hepatitis B virus (control group); women who were 
HBsAg positive and HBeAg negative (exposure group 1); 
and women who were both HBsAg and HBeAg positive 
(exposure group 2). Log-binomial regression models were 
used to estimate the risk ratios (RRs) and 95% CIs of 
preterm births for women with pre-pregnancy hepatitis B 
virus infection.
Multivariable models were used and adjusted for 
potential risk factors for preterm birth. To examine the 
robustness of our findings, we did several sensitivity 
analyses that adjusted for different covariates in the 
multivariable models. In model A, we adjusted for 
sociodemographic characteristics of women, including age 
(21–24 years, 25–29 years, 30–34 years, 35–39 years, or 
40–49 years); level of education (primary school or below, 
junior high school, senior high school, or college or 
higher); ethnic origin (Han or others); occupation (farmers, 
workers, or others); and region (eastern, central, or western 
China). In model B, we additionally adjusted for history of 
pregnancy and history of adverse pregnancy outcomes, 
including first gestation (yes or no), primipara (yes or no), 
history of preterm birth (yes or no), history of miscarriage 
(yes or no), history of stillbirth (yes or no), or history of 
induced abortion (yes or no). In model C, in addition 
to those factors included in model B, we also adjusted 
for BMI categories before pregnancy (<18·5 kg/m², 
18·5–23·9 kg/m², 24·0–27·9 kg/m², or ≥28·0 kg/m²), 
elevated alanine aminotransferase before pregnancy 
(presence or absence), smoking status of husbands during 
pregnancy (yes or no), smoking status of women during 
pregnancy (yes or no), and alcohol drinking status of 
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women during pregnancy (yes or no). Adjusted RRs and 
95% CIs of preterm births for women with pre-pregnancy 
hepatitis B virus infection were also calculated.
In the subgroup analysis, we divided women into 
different subgroups on the basis of baseline characteristics. 
Among these baseline subgroups, we examined the 
associations between maternal pre-pregnancy HBsAg 
status (regardless of HBeAg) and preterm birth after 
adjusting for other potential risk factors. All of the analyses 
were done with SAS software, version 9.4 and Stata 
software, version 14. Two-sided p values of less than 0·05 
were deemed to be statistically significant.
Role of the funding source
The funder had no role in the study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all data in the study and had final responsibility for the 
decision to submit for publication.
Results
By Dec 31, 2012, 592 247 women had pregnancy outcomes. 
We excluded 28 100 women who were not serologically 
tested for hepatitis B virus before pregnancy; 14 060 women 
with chronic diseases (including hypertension, diabetes, 
chronic nephritis, thyroid disease, heart disease, anaemia, 
and cancer); and 11 506 women with infectious disease of 
the genital tract. We excluded 20 584 women who had 
abortions, miscarriages, or stillbirths; 12 115 women with 
missing data on gestational weeks; and 15 917 women with 
multiple births or post-term pregnancies (gestation 
≥42 weeks). The remaining 489 965 women were included 
in the final analysis (figure 1). The median age of all 
women included in the study was 26 years (IQR 24–29). 
24·4% of the participants were older than 30 years, 69·4% 
had an education level of junior high school or lower, and 
67·0% were in their first pregnancy.
Overall, 20 827 (4·3%) women had pre-pregnancy 
hepatitis B virus infection; 14 979 (3·1%) tested HBsAg 
positive and HBeAg negative, and 5848 (1·2%) tested 
both HBsAg and HBeAg positive. Compared with women 
who were uninfected with hepatitis B virus, those who 
were infected with HBV were more likely to be living in 
the eastern geographical region, underweight, and smoke 
or drink alcohol (table 1).
The median length of time from pre-pregnancy 
examination to pregnancy was 2·3 months (IQR 0·8–4·5). 
25 766 of 489 965 women had preterm deliveries. The 
preterm birth rate was 5·26% (95% CI 5·20–5·32) among 
all the singleton livebirths. The preterm birth rate was 
5·2% for women who were not infected with hepatitis B 
virus, 6·5% for women who were positive for HBsAg and 
negative for HBeAg, and 6·2% for women who were 
positive for both HBsAg and HBeAg. Multivariable 
adjusted analyses showed a significant association 
between maternal pre-pregnancy hepatitis B virus 
infection and preterm birth. The unadjusted and adjusted 
RRs (aRRs) are shown in the appendix. In the fully 
adjusted model, compared with women who were not 
infected with hepatitis B virus, women who were HBsAg 
positive and HBeAg negative had a 26% higher risk of 
preterm birth, and women who were both HBsAg and 
HBeAg positive had a 20% higher risk of preterm birth 
(table 2). Adjusting for different covariates did not 
substantially affect the estimates, which were similar for 
models A, B, and C (table 2).
Among the 489 965 women included in this study, 
7019 (1·4%) showed early preterm delivery (gestation at 
less than 34 weeks). Early preterm birth occurred in 
6656 (1·4%) women who were uninfected with 
hepatitis B virus, 251 (1·7%) women who were positive 
for HBsAg and negative for HBeAg, and 112 (1·9%) 
women who were positive for both HBsAg and HBeAg, 
and these trends were significant (χtrend²=15·866, df=1, 
p<0·0001). Multivariable adjusted analyses showed a 
significant association between maternal pre-pregnancy 
hepatitis B virus infection and early preterm birth. In 
the fully adjusted model, compared with women who 
were not infected with hepatitis B virus, women who 
were HBsAg positive and HBeAg negative had a 
18% higher risk of early preterm birth and women who 
were both HBsAg and HBeAg positive had a 34% higher 
risk of early preterm birth (table 2). Adjusting for 
different covariates did not substantially influence the 
estimates, which were similar for all three models 
(table 2).
In the sensitivity analyses, the associations between 
hepatitis B virus infection and preterm birth did not 
change appreciably with additional adjustment for the 
length of time from pre-pregnancy examination to preg-
nancy (appendix p3); or exclusion of women self-reported 
Figure 1: Study profile
592 247 women had pregnancy outcomes in the NFPHEP
 from 220 counties from 2010 to 2012
564 147 women with pre-pregnancy hepatitis B virus 
 serological testing had pregnancy outcomes
489 965 women who had singleton livebirths were
 included in the final analysis
28 100 participants who did not have serological testing for hepatitis
 B virus before pregnancy were excluded
74 182 women were excluded
 14 060 women with chronic diseases
 11 506 women with genital tract infectious disease
 20 584 women with abortion (spontaneous or induced) or 
  stillbirth
 12 115 women with missing data with respect to gestational 
  weeks
 15 917 women with post-term or multiple births
See Online for appendix
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Maternal pre-pregnancy status of hepatitis B virus infection* Total (n=489 965) Preterm birth 
(n=25 766)
No infection (n=469 138) HBsAg positive and HBeAg 
negative (n=14 979)
HBsAg positive and HBeAg 
positive (n=5848)
Region
Eastern China 114 114 (24·3%) 4010 (26·8%) 1527 (26·1%) 119 651 (24·4%) 5425
Central China 260 777 (55·6%) 7944 (53·0%) 3098 (53·0%) 271 819 (55·5%) 16 526
Western China 94 247 (20·1%) 3025 (20·2%) 1223 (20·9%) 98 495 (20·1%) 3815
Age (years)
21–24 119 885 (25·6%) 3330 (22·2%) 1854 (31·7%) 125 069 (25·5%) 7012
25–29 234 966 (50·1%) 7531 (50·3%) 2988 (51·1%) 245 485 (50·1%) 12 562
30–34 85 622 (18·3%) 2942 (19·6%) 805 (13·8%) 89 369 (18·2%) 4650
35–39 22 350 (4·8%) 915 (6·1%) 158 (2·7%) 23 423 (4·8%) 1215
40–49 6315 (1·3%) 261 (1·7%) 43 (0·7%) 6619 (1·4%) 327
Education
Primary school or below 20 676 (4·4%) 628 (4·2%) 260 (4·4%) 21 564 (4·4%) 1086
Junior high school 304 513 (64·9%) 9934 (66·3%) 3872 (66·2%) 318 319 (65·0%) 17 924
Senior high school 93 146 (19·9%) 2677 (17·9%) 1145 (19·6%) 96 968 (19·8%) 4176
College or higher 50 803 (10·8%) 1740 (11·6%) 571 (9·8%) 53 114 (10·8%) 2580
Occupation
Farmer 355 920 (75·9%) 11 216 (74·9%) 4478 (76·6%) 371 614 (75·8%) 19 077
Worker 45 384 (9·7%) 1481 (9·9%) 611 (10·4%) 47 476 (9·7%) 3162
Other 67 834 (14·5%) 2282 (15·2%) 759 (13·0%) 70 875 (14·5%) 3527
Ethnic origin
Han 443 739 (94·6%) 14 337 (95·7%) 5617 (96·0%) 463 693 (94·6%) 24 310
Other 25 399 (5·4%) 642 (4·3%) 231 (4·0%) 26 272 (5·4%) 1456
History of pregnancy
History of preterm birth 783 (0·2%) 34 (0·2%) 12 (0·2%) 829 (0·2%) 68
History of miscarriage 11 257 (2·4%) 375 (2·5%) 121 (2·1%) 11 753 (2·4%) 730
History of stillbirth 3301 (0·7%) 121 (0·8%) 31 (0·5%) 3453 (0·7%) 228
History of induced abortion 58 785 (12·5%) 2134 (14·2%)) 788 (13·5%) 61 707 (12·6%) 2849
First gestation 310 387/462 276 (67·1%) 9043/14 372 (62·9%) 3780/5558 (68·0%) 323 210/482 206 
(67·0%)
16 382
Primipara 352 771/462 276 (76·3%) 10 486/14 372 (73·0%) 4408/5558 (79·3%) 367 665/482 206 
(76·2%)
18 373
Pre-pregnancy physical examination
Body-mass index (kg/m²)
Underweight (<18·5) 60 922/458 316 (13·3%) 2093/14 293 (14·6%) 978/5535 (17·7%) 63 993/478 144 
(13·4%)
3708
Normal weight (18·5–23·9) 345 486/458 316 (75·4%) 10 549/14 293 (73·8%) 3970/5535 (71·7%) 360 005/478 144 
(75·3%)
18 589
Overweight (24·0–27·9) 43 440/458 316 (9·5%) 1385/14 293 (9·7%) 490/5535 (8·9%) 45 315/478 144 
(9·5%)
2524
Obesity (≥28·0) 8468/458 316 (1·8%) 266/14 293 (1·9%) 97/5535 (1·8%) 8831/478 144 (1·8%) 486
Elevated alanine 
aminotransferase (>40 IU/L)
16 512 (3·5%) 1054 (7·0%) 948 (16·2%) 18 514 (3·8%) 1109
Lifestyle during early pregnancy
Smokes 3518/465 003 (0·8%) 115/14 772 (0·8%) 48/5751 (0·8%) 3681/485 526 (0·8%) 245
Husband smokes 131 473/465 102 (28·3%) 3920/14 771 (26·5%) 1626/5748 (28·3%) 137 019/485 621 
(28·2%)
7498
Drinks alcohol 4438/464 866 (1·0%) 150/14 772 (1·0%) 70/5749 (1·2%) 4658/485 387 (1·0%) 265
Denominators provided were some data were missing. *The distributions of pre-pregnancy status of hepatitis B virus infection with respect to different baseline 
characteristics were all statistically significant (p<0·05), except for smoking and alcohol drinking in women during pregnancy.
Table 1: Maternal baseline characteristics with respect to pre-pregnancy status of hepatitis B virus infection
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with unreliable last menstrual period or inclusion of 
women with infectious disease of the genital tract; or 
exclusion of women followed up by telephones after 
delivery (data not shown).
Compared with women who were not infected with 
HBV, those who were HBsAg positive (regardless of 
HBeAg positivity) had a 24% higher risk of preterm 
birth (aRR 1·24, 95% CI 1·18–1·31; appendix). In the 
subgroup  analyses, the associations between maternal 
pre-pregnancy hepatitis B virus infection and risk of 
preterm birth did not appear to be modified by 
baseline characteristics such as age, region, or edu-
cational level (figure 2). The association between 
maternal pre-pregnancy HBsAg positivity and risk of 
preterm birth appear to  be   somewhat greater with 
primipara or with first gestation.
Discussion
Preterm birth is one of the most common causes of 
mortality and morbidity in infants throughout the world, 
especially in low-income and middle-income countries.32 
In this large cohort of more than 490 000 women in 
China, we found that maternal infection with hepatitis B 
virus pre-pregnancy was associated with increased risk of 
preterm birth, and the  associations were consistent for 
the various subgroups of participants defined by various 
baseline characteristics.
Investigators leading several large, retrospective cohort 
studies, which were mostly done in developed countries, 
assessed the association between maternal hepatitis B 
virus infection during pregnancy and the risk of preterm 
birth.7,8 Reddick and colleagues7 used data from the 
National Inpatient Sample from the Agency for 
Healthcare Research and Quality in the USA, 
encompassing 297 664 pregnancy-related discharges 
from 1995 to 2005, and found that women with hepatitis B 
virus had an increased risk of preterm birth compared 
with women with no hepatitis B virus infection (21·9% vs 
12·1%; adjusted odds ratio [aOR] 1·65, 95% CI 1·3–2·0), 
after adjusting for maternal age, race, insurance status, 
substance use, sexually transmitted infections, and 
medical complications.7 Sirilert and colleagues12 analysed 
singleton pregnancies of 26 350 women in Thailand and 
found that the proportion of preterm births was 
significantly higher in pregnancies with positive HBsAg 
status (11·8% vs 10·0%; RR 1·013, 95% CI 1·001–1·0255), 
and preterm births were also significantly higher in 
women with positive HBeAg status (13·6% vs 8·6%; 
RR 1·250, 95% CI 1·000–1·563). Connell and colleagues8 
analysed all births in Florida, USA, from 1998 to 2007 
using 1 670 369 birth certificate records linked to hospital 
discharge data, and found that women who were 
hepatitis B virus carriers were more likely to have infants 
born preterm than those who were not infected with 
hepatitis B virus in univariate analysis (10·78% vs 8·84%, 
p<0·0001), but they did not find such an association 
using multivariable analysis after adjusting for 
sociodemographic variables, parity, obstetric compli-
cations and delivery period (aOR 1·16, 95% CI 
0·92–1·46).8 The inconsistent results among previous 
studies might be related to the various characteristics 
within the study population, such as different prevalence 
of hepatitis B virus infection and preterm births. Some 
studies done in China did not find any association 
between maternal hepatitis B virus infection and preterm 
birth.9,15,17,18 However, most of these studies were not large 
and some of them were case-control studies. The findings 
in our large cohort study were, however, consistent with 
most previous studies done in other countries, which 
found that maternal hepatitis B virus infection was 
associated with preterm birth.7,10–12 The results of 
two meta-analyses showed that hepatitis B virus infection 
was not associated with placental abruption (OR 0·98, 
95% CI 0·60–1·62),33 and found a negative association 
between hepatitis B virus infection and pre-eclampsia 
(OR 0·77, 0·65–0·90). 34 The discrepancy of the 
association between pregnant complications and 
hepatitis B virus infection might be related to the 
Outcome Model A* Model B† Model C‡
RR (95% CI) p value RR (95% CI) p value RR (95% CI) p value
Preterm birth
No infection 24 422 (5·2%) 1·00 (reference) ·· 1·00 (reference) ·· 1·00 (reference) ··
HBsAg positive and HBeAg negative 979 (6·5%) 1·26 (1·19–1·34) <0·0001 1·26 (1·19–1·34) <0·0001 1·26 (1·18–1·34) <0·0001
HBsAg positive and HBeAg positive 365 (6·2%) 1·21 (1·09–1·33) 0·0002 1·22 (1·10–1·35) 0·0001 1·20 (1·08–1·32) 0·0006
Early preterm birth
No infection 6656 (1·4%) 1·00 (reference) ·· 1·00 (reference) ·· 1·00 (reference) ··
HBsAg positive and HBeAg negative 251 (1·7%) 1·19 (1·05–1·35) 0·0059 1·18 (1·03–1·33) 0·0125 1·18 (1·04–1·34) 0·0095
HBsAg positive and HBeAg positive 112 (1·9%) 1·36 (1·12–1·63) 0·0011 1·38 (1·14–1·65) 0·0008 1·34 (1·10–1·61) 0·0025
RR=risk ratio. *Model A: risk ratios were adjusted for sociodemographic characteristics of women (age, level of education, ethnic origin, occupation, and region). †Model B: 
risk ratios were additionally adjusted for history of pregnancy (first gestation and primipara) and history of adverse pregnancy outcomes (preterm birth, spontaneous 
abortion, stillbirth, and induced abortion). ‡Model C: risk ratios were adjusted for pre-pregnancy body-mass index, pre-pregnancy elevated alanine aminotransferase, 
smoking status of husbands during pregnancy, and smoking and alcohol drinking status of women during pregnancy, in addition to the covariates in model B. 
Table 2: Adjusted RRs for preterm birth according to maternal pre-pregnancy status of hepatitis B virus infection
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different characteristics of study population, methods of 
research, sample size, and regions.
The causes of preterm birth are complex and 
multifactorial. Although the precise mechanism of 
preterm birth cannot be established in most cases,3 
the association between maternal hepatitis B virus 
infection and preterm birth might be explained by the 
accumulation of hepatitis B virus DNA in the placenta 
and trophoblast cells that might initiate the placental 
inflammatory response, a known contributor to preterm 
birth.12 Further study on the underlying mechanisms of 
hepatitis B virus infection-induced preterm birth is 
therefore required.
Our study also found that maternal pre-pregnancy 
hepatitis B virus infection was associated with an 
increased risk of early preterm birth (gestation less than 
34 weeks), with a 18% higher risk in women who were 
HBsAg positive and HBeAg negative, and a 34% higher 
risk in women who were both HBsAg and HBeAg 
positive when compared with women uninfected with 
hepatitis B virus. The following studies are among the 
few pertaining to hepatitis B virus infection and early 
preterm birth. In 2005, Tse and colleagues9 showed that 
the proportion of early preterm birth was higher for 
HBsAg-positive mothers than for HBsAg-negative 
mothers (4·7% vs 1·2%; p=0·033) in a case-control study 
of 506 Chinese women. In 2011, Elefsiniotis and 
colleagues35 found that the presence of hepatitis B 
virus-DNA in cord blood was significantly associated with 
preterm birth in pregnant women with chronic hepatitis B 
virus infection, and the relative risk of hepatitis B virus 
DNA in cord blood was 6·43 times higher in women with 
serum hepatitis B virus DNA of at least 10 000 copies 
per mL and lymphocyte count of less than 1500 than in 
those with all the other combinations of both parameters 
(p=0·001). Individuals with HBeAg-positive chronic 
infection usually exhibit high levels of hepatitis B virus 
DNA and infectiousness, and our findings also indicated 
that early preterm birth was associated with higher levels 
of hepatitis B virus infectiousness in women. Whether a 
dose-response association exists between hepatitis B 
virus DNA load and early preterm birth needs to be 
further addressed in future studies.
Liveborn preterm babies drive the need for neonatal 
care, especially for early preterm birth. In low-income 
and many middle-income settings, preterm babies do not 
have even basic care, and such babies account for most 
preterm deaths worldwide.2 There is only a 50% chance of 
survival for infants born before 34 weeks in low-income 
and middle-income countries.2,36 From a public health 
perspective and with respect to policy and planning, 
prevention of preterm births is important, especially for 
early preterm births. Our study indicated that maternal 
Adjusted risk
ratio (95% CI)
Number 
of events
Subgroup
Age (years)
21−24
25−29
30−34
35−39
40−49
Heterogeneity test: χ2=0·41; p=0·98
Education
Primary school or below
Junior high school
Senior high school
College or higher
Heterogeneity test: χ2=5·10; p=0·17
Ethnic origin
Han
Others
Heterogeneity test: χ2=0·13; p=0·71
Occupation
Farmers
Workers
Others
Heterogeneity test: χ2=6·79; p=0·03
Region
Eastern
Central
Western
Heterogeneity test: χ2=7·29; p=0·03
History of preterm birth
No
Yes
Heterogeneity test: χ2=0·01; p=0·93
History of spontaneous abortions
No
Yes
Heterogeneity test: χ2=0·06; p=0·81
History of stillbirths
No
Yes
Heterogeneity test: χ2=0·06; p=0·81
First gestation
Yes
No
Heterogeneity test: χ2=9·90; p<0·01
Primipara
Yes
No
Heterogeneity test: χ2=7·29; p=0·01
History of induced abortions
No
Yes
Heterogeneity test: χ2=1·78; p=0·18
Body-mass index
Underweight (<18·5 kg/m2)
Normal weight (18·5−23·9 kg/m2)
Overweight (24·0−27·9 kg/m2)
Obesity (≥28·0 kg/m2)
Heterogeneity test: χ2=0·75; p=0·86
Elevated alanine transaminase
No
Yes
Heterogeneity test: χ2=3·52; p=0·06
Smoking during pregnancy
No
Yes
Heterogeneity test: χ2=0·04; p=0·85
Smoking during pregnancy (husbands)
No
Yes
Heterogeneity test: χ2=0·29; p=0·59
Alcohol drinking during pregnancy
No
Yes
Heterogeneity test: χ2=0·06; p=0·81
7012
12 562
4650
1215
327
1086
17 924
4176
2580
24 310
1456
19 077
3162
3527
5425
16 526
3815
25 698
68
25 036
730
25 538
228
16 382
9145
18 373
7154
22 917
2849
3708
18 589
2524
486
24 657
1109
25 250
245
18 003
7498
25 227
265
 1·23 (1·10–1·36)
 1·25 (1·16–1·35)
 1·23 (1·08–1·40)
 1·17 (0·90–1·48)
 1·32 (0·92–1·88)
 1·46 (1·13–1·85)
 1·25 (1·17–1·33)
 1·24 (1·07–1·43)
 1·03 (0·84–1·25)
 1·25 (1·18–1·32)
 1·19 (0·91–1·52)
 1·20 (1·13–1·28)
 1·47 (1·27–1·68)
 1·22 (1·05–1·41)
 1·37 (1·22–1·53)
 1·22 (1·14–1·30)
 1·06 (0·91–1·23)
 1·24 (1·18–1·31)
 1·19 (0·51–2·80)
 1·24 (1·17–1·31)
 1·19 (0·84–1·61)
 1·24 (1·18–1·31)
 1·19 (0·85–1·62)
 1·32 (1·24–1·42)
 1·10 (1·00–1·20)
 1·30 (1·22–1·38)
 1·10 (0·99–1·22)
 1·24 (1·18–1·31)
 1·07 (0·86–1·31)
 1·18 (1·02–1·35)
 1·26 (1·18–1·34)
 1·22 (1·02–1·44)
 1·23 (0·80–1·78)
 1·27 (1·20–1·34)
 1·05 (0·86–1·26)
 1·25 (1·18–1·32)
 1·21 (0·88–1·67)
 1·23 (1·16–1·31)
 1·27 (1·15–1·40)
 1·25 (1·19–1·32)
 1·20 (0·86–1·68)
10·2 21·5
Favours preterm birthFavours term birth
Figure 2: Subgroup analyses of associations between maternal 
pre-pregnancy HBsAG positivity (regardless of HBeAg) and risk of 
preterm  birth
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pre-pregnancy hepatitis B virus infection was an 
independent risk factor of early preterm birth, and this 
risk was increased with the level of infectivity. These 
findings suggest that antiviral treatment might be 
considered (when necessary) for women who were 
infected with hepatitis B virus before pregnancy on the 
basis of their disease status and infectiousness to reduce 
the risk of preterm birth and to prevent mother-to-child 
transmission of hepatitis B virus; and monitoring the 
risk of preterm birth (especially for early preterm birth) 
by infected pregnant women should not be ignored.
This was the first explorative study of maternal 
pre-pregnancy hepatitis B virus infection and preterm 
birth in a large scale cohort in China. For this cohort, we 
recruited more than 490 000 participants, and followed up 
on pregnancy outcomes using strict quality controls. In 
this study, the number of events per variable was enough 
that the multivariable regression models were not over-
fitted. The results showed that pre-pregnancy hepatitis B 
virus infection in women increased the risk of preterm 
birth and early preterm birth. However, our study has 
some limitations. First, hepatitis B virus load was not 
available for the NFPHEP project, and, therefore, women 
who were in the window period (ie, time between first 
infection and when the serological testing could reliably 
detect the infection) might not be detected and might be 
misclassified into the control group, which could lead to 
an underestimation of the associations between maternal 
hepatitis B virus infection and preterm birth. Meanwhile, 
dose-response associations between hepatitis B virus DNA 
load and preterm birth could not be ascertained. Second, 
the NFPHEP did not collect information on pregnancy 
complications such as gestational hyper tension, gestational 
diabetes, premature rupture of membranes, or cervical 
incompetence. In the multi variable analysis, we could not 
adjust for these factors that might affect the associations 
between hepatitis B virus infection and preterm birth and 
we could not further assess the association between 
hepatitis B virus infection and different types of 
preterm birth.
Overall, in this large retrospective cohort study in rural 
China, maternal pre-pregnancy hepatitis B virus infection 
was associated with an increased risk of preterm birth. The 
NFPHEP potentially offers a unique platform to identify 
couples of a reproductive age living with hepatitis B virus 
infection who might not have progressed to late-stage liver 
disease,37 and it also provides an opportunity to provide 
counselling for hepatitis B virus-infected women to 
prevent mother-to-child transmission and reduce the risk 
of preterm birth. Given the relatively limited health 
resources and heavy burden of hepatitis B virus infection 
in rural China, early detection of hepatitis B virus infection 
before pregnancy, monitoring the risk for preterm birth, 
and providing appropriate medical intervention for women 
infected with hepatitis B virus during pregnancy would be 
helpful in improving maternal and neonatal outcomes and 
reducing child mortality.
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